Traders Continue Buying Weakness in Teva Pharma (TEVA)
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Price: $13.04 +0.23%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 2.1%
EPS Growth %: +30.0%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 2.1%
EPS Growth %: +30.0%
Join SI Premium – FREE
Teva Pharmaceutical Industries (NYSE: TEVA) is lower on the session, but market indicators hint that many are buying the opportunity.
According to recent data, money flow for Teva is $5.46 million favoring uptick purchases. The uptick-to-downtick ratio is 1.24 times.
Shares have been hit since the middle of December, down about 13 percent over the last few weeks.
Indicators also have the pharma being oversold with the 14-bar money flow index moving below the 20 percent threshold. The last time Teva made such a move was last May.
The stock is off just 0.1 percent Monday.
According to recent data, money flow for Teva is $5.46 million favoring uptick purchases. The uptick-to-downtick ratio is 1.24 times.
Shares have been hit since the middle of December, down about 13 percent over the last few weeks.
Indicators also have the pharma being oversold with the 14-bar money flow index moving below the 20 percent threshold. The last time Teva made such a move was last May.
The stock is off just 0.1 percent Monday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tuta Mail Files Google Complaint Under EU Tech Rules - Reuters
- General Motors (GM) CFO: Expect to return to profits in Q2 in China
- Visa (V) stock rises as Q2 earnings, revenue come ahead of estimates
Create E-mail Alert Related Categories
Technicals, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
